Development of NIC5-15 in the Treatment of Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborators:
Humanetics Corporation
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00470418
First received: May 4, 2007
Last updated: November 1, 2013
Last verified: October 2013

May 4, 2007
November 1, 2013
January 2007
August 2008   (final data collection date for primary outcome measure)
Pharmacokinetic analysis, Safety Assessments including vital signs, physical exam, Symptom Checklist (see below), complete blood count, serum chemistries, urinalysis, and electrocardiogram, Symptom Checklist, ADAScog [ Time Frame: Safety Labs, Physical Exams: 6 times over 7 weeks. Adverse Events assessed 21 times over the course of 7 weeks ] [ Designated as safety issue: Yes ]
Pharmacokinetic analysis, Safety Assessments including vital signs, physical exam, Symptom Checklist (see below), complete blood count, serum chemistries, urinalysis, and electrocardiogram, Symptom Checklist, ADAScog
Complete list of historical versions of study NCT00470418 on ClinicalTrials.gov Archive Site
Clinician's Global Impression of Change (ADCS-CGIC), Mini-Mental Status Exam (MMSE), Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory, Insulin Sensitivity and Secretion, Biomarkers. APO-E genotyping. [ Time Frame: safety assessed 7 times over 7 weeks, secondary outcomes assessed three times over 7 weeks ] [ Designated as safety issue: No ]
Clinician’s Global Impression of Change (ADCS-CGIC), Mini-Mental Status Exam (MMSE), Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory, Insulin Sensitivity and Secretion, Biomarkers. APO-E genotyping.
Not Provided
Not Provided
 
Development of NIC5-15 in the Treatment of Alzheimer's Disease
Development of NIC5-15 in the Treatment of Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.

Recent epidemiologic evidence, has suggested that diabetes mellitus significantly increases risk for the development of Alzheimer's disease, independent of vascular risk factors. Moreover, even patients who are simply insulin resistant, without frank diabetes, have been shown to share this elevated risk for the development of AD. As insulin's role as a neuromodulator in the brain has been revealed, several potential mechanisms for the interaction of diabetes or insulin resistance with AD have been suggested such as decreased cortical glucose utilization particularly in the hippocampus and entorhinal cortex; increased oxidative stress through the formation of advanced glycation end products; increased Tau phosphorylation and neurofibrillary tangle formation; and increased beta-amyloid aggregation through inhibition of insulin-degrading enzyme. The future treatment of AD might involve pharmacologic and dietary manipulations of insulin and glucose regulation

NIC5-15 is a single, small, naturally occurring molecule. Animal studies and some human trials have shown NIC5-15 to be safe and a potent insulin sensitizer at doses equivalent to 800-2000mg per day. In preclinical studies at doses higher than those previously studied in clinical trials, we found that NIC5-15 interferes with the accumulation of beta amyloid, an important step in the development of Alzheimer's pathology. These data suggest that NIC5-15 may be a reasonable therapeutic agent for the treatment of Alzheimer Disease for two reasons:

  1. It is a -secretase inhibitor that is Notch-sparing.
  2. It is potentially an insulin-sensitizer.

However critical safety and human efficacy studies must be conducted. This application proposes to conduct these early critical human studies. The goal of the studies contained in this proposal is to establish safety and efficacy of NIC5-15 for the treatment of AD. The specific objectives of this study are to:

Specific Objective #1) Conduct a multiple dose safety study of NIC5-15 to establish safety in the doses that appear to block amyloid accumulation. These studies will characterize the safety profile, pharmacokinetics, and tolerability

Specific Objective #2) Conduct a double blind placebo controlled pilot efficacy study of NIC5-15 in patients with AD. The goals of this study are to:

A) Demonstrate feasibility for a multi-site trial that will be used to guide the design of a future larger effort. Demonstration of feasibility will include examination of accrual rate, overall recruitment, adherence to protocol, compliance with medication and willingness to complete a randomized trial, and lack of short term toxicity.

B) Collect preliminary evidence of efficacy in terms of cognitive and global measures as well as secondary efficacy outcomes of activities of daily living, behavioral disturbances and AD biomarkers.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Alzheimer Disease
  • Dementia
  • Drug: NIC5-15
    a natural product, found in many foods and plants with mild insulin sensitizing effects
  • Drug: Placebo
    placebo comparator
  • Arm 1
    Subjects with Alzheimer's Disease
    Intervention: Drug: NIC5-15
  • Placebo Comparator: Arm 2
    Subjects with Alzheimer's Disease
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
March 2010
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • NINCDS/ADRDA criteria for probable AD
  • MMSE between 12-27
  • Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist with stable dose for at least 12 weeks
  • Home monitoring available for supervision of medications
  • Caregiver available to accompany patient to all visits and willing to participate in study as informant
  • Fluent in English or Spanish
  • Medical stability for this study as confirmed by review of records, internist's physical exam, neurological exam, and laboratory tests
  • Stable doses of non-excluded medication
  • No evidence of hepatic insufficiency
  • Able to swallow oral medications
  • Ability to participate in the informed consent process

Exclusion Criteria:

  • History of Diabetes Mellitus (OGTT criteria) requiring treatment with an excluded antidiabetic medication (see below) or history of hypoglycemia
  • Active hepatic or renal disease
  • Cardiac disease including history of congestive heart failure or current treatment for CHF; history of recent myocardial infarction
  • Use of another investigational drug within the past two months
  • History of clinically significant stroke
  • History of seizure or head trauma with disturbance of consciousness within the past two years
  • Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode within the past two years Medication Exclusion
  • Current use of oral hypoglycemic agents including sulfonylureas and meglintinides
  • Current use of a lipid-lowering agent (excluded from Study #1, see discussion below)
  • Current or past treatment with insulin for longer than two weeks
  • Current use of drugs with significant anticholinergic or antihistaminic properties
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00470418
MHBB-009-06S, R21AT003302-01A1
Yes
Department of Veterans Affairs
Department of Veterans Affairs
  • National Center for Complementary and Alternative Medicine (NCCAM)
  • Humanetics Corporation
Principal Investigator: Hillel Grossman VA Medical Center, Bronx
Department of Veterans Affairs
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP